Evidence map›Paper›PMID 42143112›Full record

ArticleScientific reports2026

Potential medical applicability of N-β-Ala and N-His dipeptidomimetics against breast cancer: short in vitro and in silico screening.

Klaudia Chmielewska, Justyna Budka, Katarzyna Kozłowska-Tylingo, Iwona Inkielewicz-Stepniak, Krystyna Dzierzbicka

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Klaudia ChmielewskaDepartment of Organic Chemistry, Faculty of Chemistry, Gdansk University of Technology, G. Narutowicza 11/12, 80233, Gdansk, Poland. klaudia.chm@gmail.com.ORCID http://orcid.org/0000-0001-5894-9508
Justyna BudkaDepartment of Pharmaceutical Pathophysiology, Medical University of Gdansk, Debinki 7, 80211, Gdansk, Poland.ORCID http://orcid.org/0000-0002-0891-1760
Katarzyna Kozłowska-TylingoDepartment of Pharmaceutical Technology and Biochemistry, Gdansk University of Technology, G. Narutowicza 11/12, 80233, Gdansk, Poland.
Iwona Inkielewicz-StepniakDepartment of Pharmaceutical Pathophysiology, Medical University of Gdansk, Debinki 7, 80211, Gdansk, Poland.ORCID http://orcid.org/0000-0003-1676-2723
Krystyna DzierzbickaDepartment of Organic Chemistry, Faculty of Chemistry, Gdansk University of Technology, G. Narutowicza 11/12, 80233, Gdansk, Poland. krydzier@pg.edu.pl.ORCID http://orcid.org/0000-0003-2447-8095

Funding

Gdansk University of Technology DS/034520Medical University of Gdansk ST-54
6 · The paper itself

Abstract

Short peptides conjugated to drugs are found to effectively improve wellbeing and recovery of cancer patients. However, to combat poor stability and bioavailability, their polar groups can be protected to form mimetics. Therefore, here we present synthesis, short biological screening and detailed computational analysis of 18 N-terminal β-alanine and L-histidine dipeptidomimetics, to estimate their preliminary relevance as cancer therapeutics intermediates for conjugation. While extended biological experiments are deeply relevant to define drug functionality, they also require extensive financial resources. Herein, we employed computational methods to better estimate possible activities of the compounds, and create a perspective between in silico and in vitro to hypothesize on the acquired results. Most efficient representatives of each group were β-Ala-Ala (BAA) and His(Bn)-Val (HV) dipeptidomimetics, which seem to show signs of selectivity. Our research provides detailed theoretical data for scientists searching for their new conjugative agents to study. We hope to encourage other experts to incorporate computational methods into their research, to increase clarity and available data for further research.

Indexed as

Antineoplastic Agentsbeta-AlanineBreast NeoplasmsHistidinePeptidomimeticsComputer SimulationFemaleHumansAntineoplastic Agentsbeta-AlanineHistidinePeptidomimeticsBeta-alanineBreast cancerHistidinePeptidePeptidomimetics

Identifiers

PMID42143112
PMCPMC13369175

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.